OS Therapies

The lead candidate is OST-HER2, an immunotherapy that uses a genetically modified strain of *Listeria monocytogenes* to stimulate T-cell responses against HER2-expressing osteosarcoma cells. The bacteria-based vector delivers HER2 antigens to the immune system, training it to attack cancer cells that overexpress HER2. A Phase 2b trial showed statistically significant improvement in event-free survival for patients with resected, recurrent osteosarcoma (per the firm's public disclosures, 2024).

Osteosarcoma occurs naturally in dogs at roughly 10–15 times the rate seen in humans, creating a large, accessible patient pool for veterinary clinical data. The company administers the same OST-HER2 formulation to canines, generating efficacy and safety signals that inform the human regulatory path and de-risk the program. This dual-track approach also opens a distinct commercial veterinary oncology market that is otherwise difficult for human-only biotech firms to access.

No. As of its public listing in August 2024, the company had no FDA-approved products and no recurring revenue. OS Therapies is a clinical-stage development company, meaning its financial position depends entirely on capital raised through equity markets and prior private financings to fund ongoing trials. The canine indication, if approved by the USDA Center for Veterinary Biologics, would be the earliest potential revenue stream.

Large pharma firms have largely deprioritized osteosarcoma because the addressable patient population — roughly 800–1,000 new US cases annually, mostly pediatric — offers limited commercial upside under typical blockbuster economics. OS Therapies is purpose-built for this narrow indication, with a bacterial-immunotherapy platform that does not require the manufacturing complexity of cell or gene therapies. The canine co-development model also provides clinical validation data that a human-only trial design cannot match.

Prior to the August 2024 direct listing, OS Therapies was capitalized by a concentrated group of high-net-worth individual investors rather than traditional venture capital funds. This structure means founder and CEO Paul Romness and a small circle of early backers likely retain significant voting control, though the exact post-IPO ownership breakdown has not been broadly disclosed in detail.

The company holds exclusive rights to a tunable Antibody Drug Conjugate platform licensed from a university collaborator. This platform is preclinical and has not yet entered human trials. It represents the firm's secondary R&D asset, with the OST-HER2 program consuming the majority of development resources and public messaging as of late 2024.

No new drug therapy has received FDA approval for osteosarcoma in over 40 years. Standard of care remains surgical resection combined with high-dose methotrexate, doxorubicin, and cisplatin — a regimen developed in the early 1980s. Patients with recurrent or metastatic disease after this frontline therapy have extremely limited options, which is the clinical gap OST-HER2 targets.